Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States of America.
Department of General Surgery, Hernia Center, St. Luke's International Hospital, Tokyo, Japan.
PLoS One. 2023 Apr 18;18(4):e0284106. doi: 10.1371/journal.pone.0284106. eCollection 2023.
Few data are available on the intensity of pain that women experience during the first five days after vaginal childbirth. Moreover, it is unknown if the use of neuraxial labor analgesia has any impact on the level of postpartum pain.
We performed a retrospective cohort study based on chart review of all women who delivered vaginally at an urban teaching hospital between April 2017 and April 2019. The primary outcome was the area under the curve of pain score on numeric rating scale (NRS) documented in electronic medical records for five days postpartum (NRS-AUC5days). Secondary outcomes included peak NRS score, doses of oral and intravenous analgesics consumed during the first five days postpartum, and relevant obstetric outcomes. Logistic regression was used to examine the associations between the use of neuraxial labor analgesia and pain-related outcomes adjusting for potential confounders.
During the study period, 778 women (38.6%) underwent vaginal delivery with neuraxial analgesia and 1240 women (61.4%) delivered without neuraxial analgesia. Median (Interquartile range) of NRS-AUC5days was 0.17 (0.12-0.24) among women who received neuraxial analgesia and 0.13 (0.08-0.19) among women who did not (p<0.001). Women who received neuraxial analgesia were more likely to require the first- and second-line analgesics postpartum than women who did not: diclofenac (87.9% vs. 73.0%, p< 0.001, respectively); acetaminophen (40.7% vs. 21.0%, p< 0.001, respectively). The use of neuraxial labor analgesia was independently associated with increased odds of having NRS-AUC5days in the highest 20 percentile (adjusted odds ratio [aOR] 2.03; 95% confidence interval [CI] 1.55-2.65), having peak NRS ≥ 4 (aOR 1.54; 95% CI 1.25-1.91) and developing hemorrhoids during the postpartum hospitalization (aOR 2.13; 95% CI 1.41-3.21) after adjusting for relevant confounders.
Although women who used neuraxial labor analgesia had slightly higher pain scores and increased analgesic requirement during postpartum hospitalization, pain after vaginal childbirth was overall mild. The small elevation in the pain burden in neuraxial group does not seem to be clinically relevant and should not influence women's choice to receive labor analgesia.
关于女性在阴道分娩后五天内经历的疼痛强度,数据很少。此外,尚不清楚使用椎管内分娩镇痛是否会对产后疼痛程度产生任何影响。
我们进行了一项回顾性队列研究,基于对 2017 年 4 月至 2019 年 4 月在一家城市教学医院阴道分娩的所有女性的图表审查。主要结局是电子病历记录的分娩后五天内数字评分量表(NRS)疼痛评分的曲线下面积(NRS-AUC5days)。次要结局包括 NRS 评分峰值、分娩后五天内口服和静脉镇痛剂的剂量以及相关产科结局。使用逻辑回归在调整潜在混杂因素后,检查椎管内分娩镇痛的使用与疼痛相关结局之间的关联。
在研究期间,778 名女性(38.6%)接受了椎管内分娩镇痛,1240 名女性(61.4%)未接受椎管内分娩镇痛。接受椎管内分娩镇痛的女性 NRS-AUC5days 的中位数(四分位距)为 0.17(0.12-0.24),而未接受椎管内分娩镇痛的女性为 0.13(0.08-0.19)(p<0.001)。与未接受椎管内分娩镇痛的女性相比,接受椎管内分娩镇痛的女性更有可能需要在产后使用一线和二线镇痛药物:双氯芬酸(87.9% vs. 73.0%,p<0.001);对乙酰氨基酚(40.7% vs. 21.0%,p<0.001)。在调整了相关混杂因素后,使用椎管内分娩镇痛与 NRS-AUC5days 处于最高 20%分位数(调整后的优势比[OR]2.03;95%置信区间[CI]1.55-2.65)、NRS 评分峰值≥4(OR 1.54;95%CI 1.25-1.91)和产后住院期间发生痔疮(OR 2.13;95%CI 1.41-3.21)的几率增加独立相关。
尽管使用椎管内分娩镇痛的女性在产后住院期间的疼痛评分和镇痛需求略有增加,但阴道分娩后的疼痛总体上是轻微的。椎管内组疼痛负担的轻微升高似乎没有临床意义,不应该影响女性接受分娩镇痛的选择。